The clinical toxicity of advanced therapy medicinal products

ATMPs offer significant therapeutic promise but require robust safety assessments and proactive risk management plans to address their complex potential toxicity profiles. Personalized approaches, advanced preclinical models and stringent regulatory oversight are essential to ensure these therapies fulfil their potential without compromising patient safety.